Every year, the iCMLf Prizes acknowledge individuals whose remarkable contributions have shaped the field of CML, driving progress in research, treatment, and care worldwide. This year, we celebrate three outstanding people whose work has transformed our understanding of CML biology, refined clinical management, and improved CML treatment and care in low- and middle-income countries.

We are delighted to announce the recipients of the 2025 iCMLf Prizes:

• Rowley Prize – Professor Satu Mustjoki (Finland)
• Goldman Prize – Dr. Delphine Rea (France)
• iCMLf Prize – Professor Nicholas Anthony Othieno-Abinya (Kenya)

Following numerous nominations received from the CML community, a panel of previous prize winners and the iCMLf Directors and Advisors has selected these exceptional individuals who have made pioneering contributions to improving the lives of people living with CML.

We are honoured to acknowledge their achievements and invite you to learn more about their groundbreaking work below.

Join us in celebrating the 2025 iCMLf Prize winners:

• Rowley Prize – Professor Satu Mustjoki
  The iCMLf Rowley Prize is awarded to individuals who have made outstanding lifetime contributions to our understanding of the biology of CML. This year’s award honours Professor Satu Mustjoki, a globally recognised expert in CML immunology. Her pioneering research has revealed key immunological mechanisms underpinning CML, including the immune-modulating effects of tyrosine kinase inhibitors (TKIs) and the role of natural killer and T cells in treatment-free remission. These discoveries have been instrumental in shaping modern therapeutic approaches and advancing immunotherapy strategies for CML.
  
  
• Goldman Prize – Dr Delphine Rea
  The iCMLf Goldman Prize recognises outstanding contributions to the clinical management of CML. Dr Delphine Réa, a distinguished hematologist based at Hôpital Saint-Louis in Paris, has been a driving force behind treatment-free remission strategies, including her involvement in pivotal studies such as the STIM and STOP 2G-TKI trials. Her research has provided critical insights into when and how patients can safely discontinue TKI therapy. She has also played a crucial role in the clinical development of targeted therapies, including asciminib, an effective option for patients with resistance or intolerance to previous TKI therapies.
  
  
• iCMLf Prize – Professor Nicholas Anthony Othieno-Abinya
  The iCMLf Prize acknowledges individuals who have made significant contributions to improving CML treatment and care in low- and middle-income countries. Professor Nicholas Abinya, a pioneering hemato-oncologist in Kenya, has been instrumental in establishing CML treatment programs across Africa. As a key figure in the Gleevec International Patient Assistance Program (GIPAP), he has facilitated access to life-saving therapies for countless patients. His commitment to mentoring the next generation of oncologists and advocating for sustainable healthcare solutions has left an enduring impact on CML care in resource-limited settings.

The 2025 iCMLf Prize winners will be honoured during award ceremonies at the 27th ESH-iCMLf John Goldman Conference on CML: Biology and Therapy in October. A highlight of the event will be their keynote presentations, offering invaluable insights into their groundbreaking work and vision for the future of CML management.

Please join us in congratulating all the prize recipients on their well-deserved recognition, on behalf of the entire CML community.